Breakthrough Pain Clinical Trial
Official title:
An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys™ Spray Compared to Actiq® for the Management of Breakthrough Pain in Chronic Pain Patients.
Chronic pain patients who experience breakthrough pain in the background of controlled persistent pain with opioids will be followed for 3 months in order to assess the safety and titration trends in the clinical practice setting of a novel fentanyl sublingual spray (Subsys™) for the treatment of breakthrough pain.
Approximately 100 subjects across 10 centers throughout the United States will be enrolled into the study. Subjects who are currently taking Actiq® for their breakthrough pain and will be discontinued due to lack of efficacy, poor tolerability, patient or prescriber dissatisfaction and meet all other study inclusion criteria and none of the exclusion criteria will be candidates to receive a sublingual fentanyl spray (Subsys™). The total duration of the study for each subject will be no more than 4 months. ;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00994760 -
Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years
|
N/A | |
| Completed |
NCT01842893 -
Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer
|
Phase 3 | |
| Completed |
NCT02886286 -
Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain
|
Phase 4 | |
| Completed |
NCT02869321 -
Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy
|
Phase 4 | |
| Completed |
NCT02840500 -
Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units
|
N/A | |
| Completed |
NCT02437929 -
Procedural Pain in Palliative Care: Prevalence, Intensity and Treatment
|
N/A | |
| Completed |
NCT00236145 -
Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain
|
Phase 3 | |
| Completed |
NCT02836379 -
Quality of Life Study Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent
|
N/A | |
| Active, not recruiting |
NCT02278601 -
Comparison of Regimens MPIB, CIPCEA, PCEA
|
Phase 3 | |
| Terminated |
NCT00842829 -
Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients
|
Phase 4 | |
| Recruiting |
NCT05200806 -
A Prospective Pilot Study of a Non-Narcotic Post-Operative Course After Colectomy
|
Phase 4 | |
| Withdrawn |
NCT03809455 -
Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients
|
Phase 2 | |
| Completed |
NCT03435120 -
Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)
|
||
| Completed |
NCT02050503 -
Intranasal Transmucosal Fentanyl Pectin for Breakthrough Cancer Pain in Radiation-induced Oropharyngeal Mucositis
|
N/A | |
| Terminated |
NCT00387010 -
Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain
|
Phase 3 | |
| Withdrawn |
NCT05053308 -
Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement
|
N/A | |
| Recruiting |
NCT04011150 -
Development of Variable Volume Automated Mandatory Boluses for Patient-controlled Epidural Analgesia During Labour
|
Phase 3 | |
| Completed |
NCT00402350 -
Staccato Fentanyl Single and Multidose PK
|
Phase 1 | |
| Completed |
NCT00236041 -
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
|
Phase 2 |